SCHEMBL6715819

SCHEMBL6715819

CC(C)(C)N(C(=O)O)C(C(=O)Nc1ccccc1C(F)(F)F)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.49
MAPK1 P28482 1/20 0.49
ALDH1A1 P00352 6/20 0.48
LMNA P02545 1/20 0.47
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NPC1 O15118 1/20 0.45
THRB P10828 1/20 0.45
RAB9A P51151 1/20 0.45
NOX1 Q9Y5S8 1/20 0.45
TSHR P16473 1/20 0.44
GAA P10253 2/20 0.44
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
GRIK1 P39086 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6716842 0.83 CYP1A2 (0.48) POLBALDH1A1LMNANPC1RAB9A
SCHEMBL6716835 0.83 CYP1A2 (0.48) POLBALDH1A1LMNANPC1RAB9A
SCHEMBL6716822 0.82 KCNQ2 (0.56) POLBMAPK1ALDH1A1LMNAKDM4E
SCHEMBL6715913 0.81 MDM4 (0.41) ALDH1A1LMNAMEN1KMT2AGAA
SCHEMBL6723623 0.81 POLB (0.51) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL6715907 0.81 KMT2A (0.50) POLBMAPK1ALDH1A1LMNAMEN1
SCHEMBL6719501 0.80 MAPT (0.46) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL6719510 0.80 MAPT (0.55) POLBALDH1A1LMNAKDM4EMEN1
SCHEMBL6723567 0.79 L3MBTL1 (0.54) ALDH1A1LMNAKDM4EMEN1KMT2A
SCHEMBL6717099 0.79 TSHR (0.53) POLBMAPK1ALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 POLB 4182/4885MAPK1 1336/4885ALDH1A1 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.